

Idaho Incubation Fund Program

Progress Report Form

Proposal No. IF14-002
Name: Dr. Greg Hampikian
Name of Institution: Boise State University
Project Title: Liposome Nullomer Peptides
Reporting Period: July 1, 2013 To December 13, 2013

Information to be reported in your progress report is as follows (attach additional information as needed):

1. Summary of project accomplishments for the period just completed and plans for the coming reporting period:

We have secured the National Cancer Institute (NCI) panel of 60 cancer cell lines and established liquid nitrogen storage in the lab, as well as culturing, freezing and testing one third of the lines against 5 of our peptide drugs.

The PI has met with private investors and corporate contacts, and will meet for a second round with two groups of investors in Nullomer technology.

We have developed two new peptide drugs with longer poly-arginine tails which improve cell penetration, and these have pushed our effective cancer killing range down to the 10 micromolar limit target. This is a minimum benchmark for the peptide drug candidates that we expect to compete against.

2. Summary of budget expenditures for the period just completed (include project burn rate):

Salaries and Fringe Benefits	\$10,544.60
Operating Expenses (Supplies)	\$ <u>5,172.56</u>
Total Expenditures	\$15,717.16

Burn Rate of 31%

3. Numbers of faculty and student participation resulting from the funding, including internships:

Faculty directly working on project: 2; affiliated: 1.

Students working on project: 3.

4. List patents, copyrights, plant variety protection certificates received or pending:
Boise State University has begun the application for patenting 198 of the Nullomer sequences and their derivatives.

5. List technology licenses signed and start-up businesses created: **NA**

6. Status of private/industry partnerships (include enough information to judge level of engagement):
PI presented research work at the International Symposium on Human Identification in Atlanta as one of the main speakers, and met with industry representatives there. A lawyer from an out-of-state investment group has contacted the PI and will meet with him in the Spring. A company out of California also requested a spring meeting.

7. Any other pertinent information that will indicate to the council that the project is meeting satisfactory progress.
We are testing more than the original 5 drugs, and will complete cancer testing 10 drugs all 60 cell lines from the NCI panel by summer.